Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.11861/11007
Title: Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease
Authors: Lee, Serene 
Yin, Liyang 
Xiao, Naomi 
Rhee, Taeho Greg 
Lo, Heidi K. Y. 
Wong, Sabrina 
Fox, Susan 
Teopiz, Kayla 
Dr. LAM Yin-Hung, Bess 
Zheng, Yang Jing 
Le, Gia Han 
Mansur, Rodrigo B. 
Rosenblat, Joshua D. 
McIntyre, Roger S. 
Issue Date: 2025
Source: CNS Spectrums, 2025, vol. 30(1), article no. e44.
Journal: CNS Spectrums 
Abstract: Parkinson’s disease (PD) is a severe neurodegenerative disorder characterized by prominent motor and non-motor (e.g., cognitive) abnormalities. Notwithstanding Food and Drug Administration (FDA)-approved treatments (e.g., L-dopa), most persons with PD do not adequately benefit from the FDA-approved treatments and treatment emergent adverse events are often reasons for discontinuation. To date, no current therapy for PD is disease modifying or curative. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are central nervous system (CNS) penetrant and have shown to be neuroprotective against oxidative stress, neuroinflammation, and insulin resistance, as well as promoting neuroplasticity. Preclinical evidence suggests that GLP-1RAs also attenuate the accumulation of α-synuclein. The cellular and molecular effects of GLP-1RAs provide a basis to hypothesize putative therapeutic benefit in individuals with PD. Extant preclinical and clinical trial evidence in PD provide preliminary evidence of clinically meaningful benefit in the cardinal features of PD. Herein, we synthesize extant preclinical and early-phase clinical evidence, suggesting that GLP-1RAs may be beneficial as a treatment and/or illness progression modification therapeutic in PD.
Type: Peer Reviewed Journal Article
URI: http://hdl.handle.net/20.500.11861/11007
ISSN: 1092-8529
2165-6509
DOI: 10.1017/S109285292510031X
Appears in Collections:Counselling and Psychology - Publication

Show full item record

Page view(s)

7
checked on Jul 4, 2025

Google ScholarTM

Impact Indices

Altmetric

PlumX

Metrics


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.